Osteosarcoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	IE Sensitive: A2 - Guideline IE Sensitive : A2	IE Sensitive: A2 - Guideline IE Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	gemcitabine + docetaxel + cyclophosphamide Sensitive: A2 - Guideline gemcitabine + docetaxel + cyclophosphamide Sensitive : A2	gemcitabine + docetaxel + cyclophosphamide Sensitive: A2 - Guideline gemcitabine + docetaxel + cyclophosphamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + cyclophosphamide + etoposide IV Sensitive: A2 - Guideline carboplatin + cyclophosphamide + etoposide IV Sensitive : A2	carboplatin + cyclophosphamide + etoposide IV Sensitive: A2 - Guideline carboplatin + cyclophosphamide + etoposide IV Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + cyclophosphamide Sensitive: A2 - Guideline carboplatin + cyclophosphamide Sensitive : A2	carboplatin + cyclophosphamide Sensitive: A2 - Guideline carboplatin + cyclophosphamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cyclophosphamide + etoposide IV Sensitive: A2 - Guideline cyclophosphamide + etoposide IV Sensitive : A2	cyclophosphamide + etoposide IV Sensitive: A2 - Guideline cyclophosphamide + etoposide IV Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	gemcitabine + docetaxel + ifosfamide Sensitive: A2 - Guideline gemcitabine + docetaxel + ifosfamide Sensitive : A2	gemcitabine + docetaxel + ifosfamide Sensitive: A2 - Guideline gemcitabine + docetaxel + ifosfamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline carboplatin + ifosfamide + etoposide IV Sensitive : A2	carboplatin + ifosfamide + etoposide IV Sensitive: A2 - Guideline carboplatin + ifosfamide + etoposide IV Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	carboplatin + ifosfamide Sensitive: A2 - Guideline carboplatin + ifosfamide Sensitive : A2	carboplatin + ifosfamide Sensitive: A2 - Guideline carboplatin + ifosfamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive : A2	cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	ifosfamide + methotrexate + etoposide oral Sensitive: A2 - Guideline ifosfamide + methotrexate + etoposide oral Sensitive : A2	ifosfamide + methotrexate + etoposide oral Sensitive: A2 - Guideline ifosfamide + methotrexate + etoposide oral Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	sorafenib + everolimus Sensitive: A2 - Guideline sorafenib + everolimus Sensitive : A2	sorafenib + everolimus Sensitive: A2 - Guideline sorafenib + everolimus Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	gemcitabine + docetaxel Sensitive: A2 - Guideline gemcitabine + docetaxel Sensitive : A2	gemcitabine + docetaxel Sensitive: A2 - Guideline gemcitabine + docetaxel Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cyclophosphamide + topotecan Sensitive: A2 - Guideline cyclophosphamide + topotecan Sensitive : A2	cyclophosphamide + topotecan Sensitive: A2 - Guideline cyclophosphamide + topotecan Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cisplatin + doxorubicin hydrochloride + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + methotrexate Sensitive : A2	cisplatin + doxorubicin hydrochloride + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + methotrexate Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cisplatin + doxorubicin hydrochloride Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride Sensitive : A2	cisplatin + doxorubicin hydrochloride Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride Sensitive : A2
TMB-H	Osteosarcoma	TMB-H	Osteosarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Osteosarcoma	MSI-H/dMMR	Osteosarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	MAP Sensitive: A2 - Guideline MAP Sensitive : A2	MAP Sensitive: A2 - Guideline MAP Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
NTRK2 fusion	Osteosarcoma	NTRK2 fusion	Osteosarcoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK1 fusion	Osteosarcoma	NTRK1 fusion	Osteosarcoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK3 fusion	Osteosarcoma	NTRK3 fusion	Osteosarcoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
CDK4 overexpression	Osteosarcoma	CDK4 overexpression	Osteosarcoma	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
ERCC1 K504Q	Osteosarcoma	ERCC1 K504Q	Osteosarcoma	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3	cisplatin Resistant: C3 – Early Trials cisplatin Resistant : C3

Osteosarcoma

Associations(54)

Associations
(54)